454 related articles for article (PubMed ID: 33325754)
1. Enfortumab vedotin - next game-changer in urothelial cancer.
Maas M; Stühler V; Walz S; Stenzl A; Bedke J
Expert Opin Biol Ther; 2021 Jul; 21(7):801-809. PubMed ID: 33325754
[No Abstract] [Full Text] [Related]
2. Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma.
McGregor BA; Sonpavde G
Expert Opin Investig Drugs; 2019 Oct; 28(10):821-826. PubMed ID: 31526130
[No Abstract] [Full Text] [Related]
3. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.
Mantia CM; Sonpavde G
Expert Rev Anticancer Ther; 2022 May; 22(5):449-455. PubMed ID: 35466857
[TBL] [Abstract][Full Text] [Related]
4. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
Yu EY; Petrylak DP; O'Donnell PH; Lee JL; van der Heijden MS; Loriot Y; Stein MN; Necchi A; Kojima T; Harrison MR; Hoon Park S; Quinn DI; Heath EI; Rosenberg JE; Steinberg J; Liang SY; Trowbridge J; Campbell M; McGregor B; Balar AV
Lancet Oncol; 2021 Jun; 22(6):872-882. PubMed ID: 33991512
[TBL] [Abstract][Full Text] [Related]
5. The biology and rationale of targeting nectin-4 in urothelial carcinoma.
Heath EI; Rosenberg JE
Nat Rev Urol; 2021 Feb; 18(2):93-103. PubMed ID: 33239713
[TBL] [Abstract][Full Text] [Related]
6. Enfortumab Vedotin in urothelial cancer.
Alt M; Stecca C; Tobin S; Jiang DM; Sridhar SS
Ther Adv Urol; 2020; 12():1756287220980192. PubMed ID: 33447264
[TBL] [Abstract][Full Text] [Related]
7. Enfortumab vedotin to treat urothelial carcinoma.
Hanna KS
Drugs Today (Barc); 2020 May; 56(5):329-335. PubMed ID: 32406880
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
Koshkin VS; Henderson N; James M; Natesan D; Freeman D; Nizam A; Su CT; Khaki AR; Osterman CK; Glover MJ; Chiang R; Makrakis D; Talukder R; Lemke E; Olsen TA; Jain J; Jang A; Ali A; Jindal T; Chou J; Friedlander TW; Hoimes C; Basu A; Zakharia Y; Barata PC; Bilen MA; Emamekhoo H; Davis NB; Shah SA; Milowsky MI; Gupta S; Campbell MT; Grivas P; Sonpavde GP; Kilari D; Alva AS
Cancer; 2022 Mar; 128(6):1194-1205. PubMed ID: 34882781
[TBL] [Abstract][Full Text] [Related]
9. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma.
Halford Z; Anderson MK; Clark MD
Ann Pharmacother; 2021 Jun; 55(6):772-782. PubMed ID: 32945172
[TBL] [Abstract][Full Text] [Related]
10. Enfortumab vedotin in the treatment of urothelial cancers and beyond.
Wong RL; Yu EY
Future Oncol; 2022 Sep; 18(27):3067-3084. PubMed ID: 36004667
[TBL] [Abstract][Full Text] [Related]
11. Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma.
Hanna KS
Drugs; 2020 Jan; 80(1):1-7. PubMed ID: 31823332
[TBL] [Abstract][Full Text] [Related]
12. Enfortumab Vedotin: Nursing Perspectives on the Management of Adverse Events in Patients With Locally Advanced or Metastatic Urothelial Carcinoma.
Pace A; Brower B; Conway D; Leis D
Clin J Oncol Nurs; 2021 Apr; 25(2):E1-E9. PubMed ID: 33739346
[TBL] [Abstract][Full Text] [Related]
13. EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.
Rosenberg J; Sridhar SS; Zhang J; Smith D; Ruether D; Flaig TW; Baranda J; Lang J; Plimack ER; Sangha R; Heath EI; Merchan J; Quinn DI; Srinivas S; Milowsky M; Wu C; Gartner EM; Zuo P; Melhem-Bertrandt A; Petrylak DP
J Clin Oncol; 2020 Apr; 38(10):1041-1049. PubMed ID: 32031899
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma.
Takahashi S; Uemura M; Kimura T; Kawasaki Y; Takamoto A; Yamaguchi A; Melhem-Bertrandt A; Gartner EM; Inoue T; Akazawa R; Kadokura T; Tanikawa T
Invest New Drugs; 2020 Aug; 38(4):1056-1066. PubMed ID: 31444589
[TBL] [Abstract][Full Text] [Related]
15. Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.
Uchimoto T; Tsuchida S; Komura K; Fukuokaya W; Adachi T; Hirasawa Y; Hashimoto T; Yoshizawa A; Saruta M; Hashimoto M; Higashio T; Matsuda T; Nishimura K; Tsujino T; Nakamura K; Fukushima T; Nishio K; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Takahara K; Inamoto T; Miki J; Fujita K; Kimura T; Ohno Y; Shiroki R; Uemura H; Azuma H
Target Oncol; 2024 May; 19(3):401-410. PubMed ID: 38546942
[TBL] [Abstract][Full Text] [Related]
16. Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options.
Park I; Lee JL
Korean J Intern Med; 2020 Jul; 35(4):834-853. PubMed ID: 32668516
[TBL] [Abstract][Full Text] [Related]
17. [New paradigms in the second line treatment for advanced and metastatic urothelial carcinoma.].
Vidal N; Puente J
Arch Esp Urol; 2020 Dec; 73(10):1007-1015. PubMed ID: 33269719
[TBL] [Abstract][Full Text] [Related]
18. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
Powles T; Rosenberg JE; Sonpavde GP; Loriot Y; Durán I; Lee JL; Matsubara N; Vulsteke C; Castellano D; Wu C; Campbell M; Matsangou M; Petrylak DP
N Engl J Med; 2021 Mar; 384(12):1125-1135. PubMed ID: 33577729
[TBL] [Abstract][Full Text] [Related]
19. Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectives.
Iacovelli R; Cicala CM; Ciccarese C; Sacco E; Racioppi M; Bassi PF; Tortora G
Urologia; 2023 Feb; 90(1):3-10. PubMed ID: 36537831
[TBL] [Abstract][Full Text] [Related]
20. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.
Rosenberg JE; Powles T; Sonpavde GP; Loriot Y; Duran I; Lee JL; Matsubara N; Vulsteke C; Castellano D; Mamtani R; Wu C; Matsangou M; Campbell M; Petrylak DP
Ann Oncol; 2023 Nov; 34(11):1047-1054. PubMed ID: 37678672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]